Supriya Lifescience Q2 Revenue Up 19%, Driven By Anaesthetic Segment

Supriya Lifescience, a leading manufacturer of active pharmaceutical ingredients (APIs), revealed robust financial results for Q2 FY25, with revenue growth of 18.6 per cent year-on-year to Rs 166.1 crore, up from Rs 140.1 crore in the same quarter last year. The significant growth in Q2 was primarily driven by the anaesthetic and analgesic segment, which contributed 54.9 per cent to the overall revenue, compared to 50 per cent in the previous year.

For Q2 FY25, the company’s gross profit surged by 53.1 per cent to Rs 120.13 crore, and EBITDA saw a rise of 103.8 per cent, reaching Rs 64.72 crore. Supriya Lifescience's profit after tax (PAT) rose by 93.2 per cent, totalling Rs 46.15 crore, compared to Rs 23.88 crore in Q2 FY24. EBITDA margins also grew to 39.0 per cent, reflecting the company’s emphasis on cost efficiency and enhanced capacity utilisation.

Dr. Satish Wagh, Executive Chairman, Supriya Lifescience, noted, “Our focus on innovation and R&D is driving sustainable growth. With our upcoming facility in Ambernath and expanded capacity in Lote Parshuram, we’re positioning ourselves for continued growth in both domestic and international markets. Our recent 10-year contract with a major European company highlights our expertise in handling complex chemical processes, setting the groundwork for future opportunities.”

Key Growth Factors 
Capacity Utilisation: The company achieved 86 per cent capacity utilisation, up from 47 per cent in FY22, following the recent capacity expansion at its Lote Parshuram facility.

Global Market Penetration: Supriya Lifescience’s European market share grew to 45 per cent of total revenue for H1 FY25, underscoring the company’s strategy of expanding its footprint in regulated markets.

Enhanced Production Capacity: In Q3 FY25, the company plans to further increase its production capacity to 1,020 KL at the Lote Parshuram facility.

Focused Segments: The anaesthetic and analgesic segment continues to drive growth, complemented by the anti-asthmatic segment, which increased its revenue contribution to 9.2 per cent in Q2 FY25.

Supriya Lifescience serves over 1,700 customers across 128 countries, leveraging its strategic partnerships and compliance with international standards. The company remains well-positioned to continue its upward trajectory in the growing API market, particularly in Europe and other regulated regions.